Management of hyperglycaemia in Cushing's disease: Experts' proposals on the use of pasireotide

Diabetes and Metabolism

Volumn 39, Issue 1, 2013, Pages 34-41

  Reznik, Y ^a   Bertherat, J ^b   Borson Chazot, F ^c,d   Brue, T ^e   Chanson, P ^f   Cortet Rudelli, C ^g   Delemer, B ^h   Tabarin, A ⁱ   Bisot Locard, S ^j   Verges B ^k  

^a CHU CÔTE DE NACRE   (France)

^b Hôpital Cochin ^*  (France)

^c UNIVERSITÉ LYON 1   (France)

^d CENTRE DE RECHERCHE EN CANCÉROLOGIE DE LYON   (France)

^e University of Mediterranée   (France)

^f BICÊTRE HOSPITAL   (France)

^g LILLE UNIVERSITY HOSPITAL   (France)

^h SERVICE DE DERMATOLOGIE   (France)

ⁱ BORDEAUX UNIVERSITY HOSPITAL   (France)

^j NOVARTIS PHARMA K K   (Japan)

^k HÔPITAL DU BOCAGE   (France)

more..

Author keywords

Cushing's disease; Diabetes; Glucose metabolism; Pasireotide; Review; Secondary diabetes

Indexed keywords

ANGIOPEPTIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1; GLUCOCORTICOID; GLUCOKINASE; GLUCOSE; GLUCOSE TRANSPORTER 2; HEMOGLOBIN A1C; INSULIN; LIRAGLUTIDE; METFORMIN; NATEGLINIDE; OCTREOTIDE; ORAL ANTIDIABETIC AGENT; PASIREOTIDE; SULFONYLUREA; VILDAGLIPTIN;

ARTICLE; BLOOD GLUCOSE MONITORING; CONTINUOUS INFUSION; CUSHING DISEASE; DIABETES MELLITUS; DIABETOGENESIS; DRUG EFFECT; DRUG SAFETY; DRUG WITHDRAWAL; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLYCEMIC CONTROL; HUMAN; HYPERCORTISOLISM; HYPERGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; KETOACIDOSIS; NONHUMAN; NONKETOTIC DIABETIC COMA; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PREVALENCE; RISK BENEFIT ANALYSIS; SINGLE DRUG DOSE;

BIOLOGICAL MARKERS; BLOOD GLUCOSE; CLINICAL TRIALS AS TOPIC; DRUG THERAPY, COMBINATION; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYDROCORTISONE; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; METFORMIN; MULTICENTER STUDIES AS TOPIC; PITUITARY ACTH HYPERSECRETION; PITUITARY GLAND; PITUITARY HORMONES; PRACTICE GUIDELINES AS TOPIC; RECURRENCE; SOMATOSTATIN;

EID: 84874313212     PISSN: 12623636     EISSN: 18781780     Source Type: Journal    
DOI: 10.1016/j.diabet.2012.10.005     Document Type: Article

References (31)

1. Syndrome de Cushing, protocole national de diagnostic et de soins, HAS, septembre 2008.
2. Castinetti F., Morange I., Conte-Devolx B., Brue T. Cushing's disease. Orphanet J Rare Dis 2012, 7:41.
3. Dekkers O.M., Biermasz N.R., Pereira A.M., Roelfsema F., van Aken M.O., Voormolen J.H., et al. Mortality in patients treated for Cushing's disease is increased, compared with patients treated for nonfunctioning pituitary macroadenoma. J Clin Endocrinol Metab 2007, 92:976-981.
4. Clayton R.N., Raskauskiene D., Reulen R.C., Jones P.W. Mortality and morbidity in Cushing's disease over 50 years in Stoke-on-Trent, UK: audit and meta-analysis of literature. J Clin Endocrinol Metab 2011, 96:632-642.
5. Colao A., Pivonello R., Spiezia S., Faggiano A., Ferone D., Filippella M., et al. Persistence of increased cardiovascular risk in patients with Cushing's disease after five years of successful cure. J Clin Endocrinol Metab 1999, 84:2664-2672.
6. Lindsay J.R., Nansel T., Baid S., Gumowski J., Nieman L.K. Long-term impaired quality of life in Cushing's syndrome despite initial improvement after surgical remission. J Clin Endocrinol Metab 2006, 91:447-453.
7. van der Hoek J., Lamberts S.W., Hofland L.J. Preclinical and clinical experiences with the role of somatostatin receptors in the treatment of pituitary adenomas. Eur J Endocrinol 2007, 156(Suppl. 1):S45-S51.
8. Colao A., Petersenn S., Newell-Price J., Findling J.W., Gu F., Maldonado M., et al. A 12-month phase 3 study of pasireotide in Cushing's disease. N Engl J Med 2012, 366:914-924.
9. Mazziotti G., Gazzaruso C., Giustina A. Diabetes in Cushing syndrome: basic and clinical aspects. Trends Endocrinol Metab 2011, 22:499-506.
10. Baudry C., Martinie M., Fathallah-Sahnoun M., Gatta-Cherifi B., Bou Khalil R., Guignat L., et al. Initial management and complications of Cushing disease (CD): a French multicenter study of 437 patients. Endocr Abstr 2011, 26:P252.
11. Valassi E., Santos A., Yaneva M., Tóth M., Strasburger C.J., Chanson P., et al. The European registry on Cushing's syndrome: 2-year experience. Baseline demographic and clinical characteristics. Eur J Endocrinol 2011, 165:383-392.
12. Mancini T., Kola B., Mantero F., Boscaro M., Arnaldi G. High cardiovascular risk in patients with Cushing's syndrome according to 1999 WHO/ISH guidelines. Clin Endocrinol (Oxf) 2004, 61:768-777.
13. Arnaldi G., Mancini T., Polenta B., Boscaro M. Cardiovascular risk in Cushing's syndrome. Pituitary 2004, 7:253-256.
14. Etxabe J., Vazquez J.A. Morbidity and mortality in Cushing's disease: an epidemiological approach. Clin Endocrinol (Oxf) 1994, 40:479-484.
15. van Raalte D.H., Ouwens D.M., Diamant M. Novel insights into glucocorticoid-mediated diabetogenic effects: towards expansion of therapeutic options?. Eur J Clin Invest 2009, 39:81-93.
16. Hansen K.B., Vilsbøll T., Bagger J.I., Holst J.J., Knop F.K. Reduced glucose tolerance and insulin resistance induced by steroid treatment, relative physical inactivity, and high-calorie diet impairs the incretin effect in healthy subjects. J Clin Endocrinol Metab 2010, 95:3309-3317.
17. van Raalte D.H., van Genugten R.E., Linssen M.M., Ouwens D.M., Diamant M. Glucagon-like peptide-1 receptor agonist treatment prevents glucocorticoid-induced glucose intolerance and islet-cell dysfunction in humans. Diabetes Care 2011, 34:412-417.
18. Ritzel R.A., Kleine N., Holst J.J., Willms B., Schmiegel W., Nauck M.A. Preserved GLP-1 effects in a diabetic patient with Cushing's disease. Exp Clin Endocrinol Diabetes 2007, 115:146-150.
19. Kola B., Christ-Crain M., Lolli F., Arnaldi G., Giacchetti G., Boscaro M., et al. Changes in adenosine 5'-monophosphate-activated protein kinase as a mechanism of visceral obesity in Cushing's syndrome. J Clin Endocrinol Metab 2008, 93:4969-4973.
20. Pivonello R., De Leo M., Vitale P., Cozzolino A., Simeoli C., De Martino M.C., et al. Pathophysiology of diabetes mellitus in Cushing's syndrome. Neuroendocrinology 2010, 92(Suppl. 1):77-81.
21. Nosadini R., Del Prato S., Tiengo A., Valerio A., Muggeo M., Opocher G., et al. Insulin resistance in Cushing's syndrome. J Clin Endocrinol Metab 1983, 57:529-536.
22. Clore J.N., Thurby-Hay L. Glucocorticoid-induced hyperglycemia. Endocr Pract 2009, 15:469-474.
23. Burt M.G., Roberts G.W., Aguilar-Loza N.R., Frith P., Stranks S.N. Continuous monitoring of circadian glycemic patterns in patients receiving prednisolone for COPD. J Clin Endocrinol Metab 2011, 96:1789-1796.
24. Arnaldi G., Angeli A., Atkinson A.B., Bertagna X., Cavagnini F., Chrousos G.P., et al. Diagnosis and complications of Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab 2003, 88:5593-5602.
25. Zambre Y., Ling Z., Chen M.C., Hou X., Woon C.W., Culler M., et al. Inhibition of human pancreatic islet insulin release by receptor-selective somatostatin analogs directed to somatostatin receptor subtype 5. Biochem Pharmacol 1999, 57:1159-1164.
26. Singh V., Brendel M.D., Zacharias S., Mergler S., Jahr H., Wiedenmann B., et al. Characterization of somatostatin receptor subtype-specific regulation of insulin and glucagon secretion: an in vitro study on isolated human pancreatic islets. J Clin Endocrinol Metab 2007, 92:673-680.
27. Schmid H.A., Brueggen J. Effects of somatostatin analogs on glucose homeostasis in rats. J Endocrinol 2012, 212:49-60.
28. Henry R.R., Mudaliar S., Hermosillo Reséndiz K., Ligueros-Saylan M., Chenji S., Golor G. Mechanism and management of hyperglycemia associated with pasireotide: results from studies in healthy volunteers. Endocr Abstr 2011, 26:P26.
29. Boscaro M., Ludlam W.H., Atkinson B., Glusman J.E., Petersenn S., Reincke M., et al. Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial. J Clin Endocrinol Metab 2009, 94:115-122.
30. Standards of medical care in diabetes-2012. Diabetes Care 2012;35 (Suppl. 1):S11-S63.
31. Inzucchi S.E., Bergenstal R.M., Buse J.B., Diamant M., Ferrannini E., Nauck M., et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American diabetes association (ADA) and the European association for the study of diabetes (EASD). Diabetes Care 2012, 35:1364-1379.